Aurobindo Pharma launches Cinacalcet Hydrochloride Tablets in US market

Aurobindo Pharma has launched Cinacalcet Hydrochloride Tablets (30mg, 60mg and 90mg) at risk in the US market in accordance with the terms of settlement agreement with Amgen Inc, Aurobindo's Cinacalcet Hydrochloride tablets 30mg, 60mg and 90mg is a generic version of Amgen Inc's Sensipar tablets, Cinacalcet Hydrochloride tablets had an annual sale of approximately US$ 1,449 million for the twelve months ending May 2019 as per IQVIA.

Cinacalcet Hydrochloride tablets are indicated for the treatment of:
Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKO) on dialysis
Hypercalcemia in adult patients with parathyroid carcinoma
Severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy